Tatva Chintan Pharma Chem Limited (NSE:TATVA)

Market Cap	26.51B +53.4%
Revenue (ttm)	5.06B +32.2%
Net Income	420.54M +636.1%
EPS	17.98 +636.9%
Shares Out	23.39M
PE Ratio	63.03
Forward PE	42.76
Dividend	2.00 (0.18%)
Ex-Dividend Date	Sep 12, 2025

Volume	127,065
Open	1,146.80
Previous Close	1,146.80
Day's Range	1,107.10 - 1,171.80
52-Week Range	881.00 - 1,610.00
Beta	0.52
Analysts	Hold
Price Target	1,390.00 (+22.66%)
Earnings Date	May 16, 2026

About Tatva Chintan Pharma Chem

Tatva Chintan Pharma Chem Limited engages in the manufacture and sale of specialty chemicals in India, Germany, the United States of America, China, Singapore, and internationally. It offers structure directing agents (SDAs); phase transfer catalysts (PTCs); electrolyte salts for super capacitor batteries; pharmaceutical and agrochemical intermediates, and other specialty chemicals (PASC); and brominated flame retardants. The company serves automotive, refinery, pharmaceutical, agrochemicals, paints and coatings, dyes and pigments, personal car...

• Industry: Specialty Chemicals
• Sector: Materials
• Founded: 1996
• Employees: 679
• Stock Exchange: National Stock Exchange of India
• Ticker Symbol: TATVA

Financial Performance

In fiscal year 2026, Tatva Chintan Pharma Chem's revenue was 5.06 billion, an increase of 32.18% compared to the previous year's 3.83 billion. Earnings were 420.54 million, an increase of 636.11%.